{
  "id": 19247197,
  "title": "M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial",
  "url": "https://urgent.news/2026/11/09/m1-m4-agonist-relieved-schizophrenia-symptoms-in-mid-stage-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T22:04:47.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/neicongress/123795"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}